Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1989 Nov;60(5):764–766. doi: 10.1038/bjc.1989.355

Symptom relief with moderate dose chemotherapy (mitomycin-C, vinblastine and cisplatin) in advanced non-small cell lung cancer.

J R Hardy 1, T Noble 1, I E Smith 1
PMCID: PMC2247325  PMID: 2478183

Abstract

Twenty-four symptomatic patients with advanced non-small cell lung cancer (NSCLC) were treated with cisplatin-based chemotherapy (mitomycin-C 8 mg m-2 q 6 weeks, vinblastine 6 mg m-2 q 3 weeks, cisplatin 50 mg m-2 q 3 weeks). Patients were assessed for symptom relief as well as for objective response. Although only five patients achieved an objective response (21%), 18 patients (75%) reported a complete disappearance or good improvement in at least one of their tumour-related symptoms. The overall symptomatic response rate was 67% with 16 patients feeling better or much better on treatment. The toxicity of treatment (primarily myelosuppression and nausea and vomiting) was mild and hair loss was minimal. The high incidence of symptomatic relief seen in this study, even in the absence of objective response, suggests that moderate dose chemotherapy may have a role in the palliation of NSCLC.

Full text

PDF
764

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bakowski M. T., Crouch J. C. Chemotherapy of non-small cell lung cancer: a reappraisal and a look to the future. Cancer Treat Rev. 1983 Sep;10(3):159–172. doi: 10.1016/0305-7372(83)90030-0. [DOI] [PubMed] [Google Scholar]
  2. Cormier Y., Bergeron D., La Forge J., Lavandier M., Fournier M., Chenard J., Desmeules M. Benefits of polychemotherapy in advanced non-small-cell bronchogenic carcinoma. Cancer. 1982 Sep 1;50(5):845–849. doi: 10.1002/1097-0142(19820901)50:5<845::aid-cncr2820500507>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  3. Cullen M. H., Joshi R., Chetiyawardana A. D., Woodroffe C. M. Mitomycin, ifosfamide and cis-platin in non-small cell lung cancer: treatment good enough to compare. Br J Cancer. 1988 Sep;58(3):359–361. doi: 10.1038/bjc.1988.219. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Elliott J. A. Is there standard chemotherapy for non-small cell lung cancer? Eur J Cancer Clin Oncol. 1986 Apr;22(4):369–371. doi: 10.1016/0277-5379(86)90100-8. [DOI] [PubMed] [Google Scholar]
  5. Folman R. S., Rosman M. The role of chemotherapy in non-small cell lung cancer: the community perspective. Semin Oncol. 1988 Jun;15(3 Suppl 4):16–21. [PubMed] [Google Scholar]
  6. Giaccone G., Bagatella M., Donadio M., Bonardi G. M., Testore F., Ferrati P., Ciuffreda L., Calciati A. Mitomycin C, vinblastine and cis-platin. An active regimen for advanced non-small cell lung cancer. Br J Cancer. 1987 Oct;56(4):475–478. doi: 10.1038/bjc.1987.227. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Gralla R. J., Casper E. S., Kelsen D. P., Braun D. W., Jr, Dukeman M. E., Martini N., Young C. W., Golbey R. B. Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: A randomized trial investigating two dosage schedules. Ann Intern Med. 1981 Oct;95(4):414–420. doi: 10.7326/0003-4819-95-4-414. [DOI] [PubMed] [Google Scholar]
  8. Hoffman P. C., Bitran J. D., Golomb H. M. Chemotherapy of metastatic non-small cell bronchogenic carcinoma. Semin Oncol. 1983 Mar;10(1):111–122. [PubMed] [Google Scholar]
  9. Lad T. E., Nelson R. B., Diekamp U., Kukla L. J., Sarma P. R., Larson C. S., Currie E. T., Chawla M. S., Tichler T., Zawila P. Immediate versus postponed combination chemotherapy (CAMP) for unresectable non-small cell lung cancer: a randomized trial. Cancer Treat Rep. 1981 Nov-Dec;65(11-12):973–978. [PubMed] [Google Scholar]
  10. Laing A. H., Berry R. J., Newman C. R., Peto J. Treatment of inoperable carcinoma of bronchus. Lancet. 1975 Dec 13;2(7946):1161–1164. doi: 10.1016/s0140-6736(75)92654-9. [DOI] [PubMed] [Google Scholar]
  11. Mackillop W. J., O'Sullivan B., Ward G. K. Non-small cell lung cancer: how oncologists want to be treated. Int J Radiat Oncol Biol Phys. 1987 Jun;13(6):929–934. doi: 10.1016/0360-3016(87)90109-x. [DOI] [PubMed] [Google Scholar]
  12. Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207–214. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  13. Rapp E., Pater J. L., Willan A., Cormier Y., Murray N., Evans W. K., Hodson D. I., Clark D. A., Feld R., Arnold A. M. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial. J Clin Oncol. 1988 Apr;6(4):633–641. doi: 10.1200/JCO.1988.6.4.633. [DOI] [PubMed] [Google Scholar]
  14. Sculier J. P., Klastersky J. Progress in chemotherapy of non-small cell lung cancer. Eur J Cancer Clin Oncol. 1984 Nov;20(11):1329–1333. doi: 10.1016/0277-5379(84)90049-x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES